Function of RELMβ in oral tolerance breakdown in food allergy

RELMβ 在食物过敏口服耐受破坏中的作用

• 批准号: 10301157
• 负责人: Elena Crestani
• 金额: $ 19.49万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-06-09 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10301157
• 关键词: Address; Affect; Age; Allergens; Allergic; Allergic Disease; Anaphylaxis; Asthma; Atopic Dermatitis; Award; Biological Markers; Biometry; Caring; Cells; Child; Childhood; Clinical; Clinical effectiveness; Communities; Data Analyses; Development; Diagnosis; Disease; Disease Outcome; Environment; Environmental Risk Factor; Epidemic; Epidemiology; Equilibrium; Evaluation; Five-Year Plans; Food; Food Hypersensitivity; Foundations; Frequencies; Funding; Future; GATA3 gene; Generations; Genetic; Goals; Head; Health; Human; IgE; Immune; Impairment; Individual; Institution; Interleukin-4; Investigation; Knowledge; Laboratories; Learning; Life; Life Style; Master of Public Health; Mediating; Mentors; Modernization; Molecular; Mucous Membrane; Mus; Pathogenesis; Pathogenicity; Patients; Physicians; Plasma; Play; Positioning Attribute; Prevalence; Production; Public Health; Public Health Schools; Quality of life; Regulation; Regulatory T-Lymphocyte; Research; Research Personnel; Resolution; Resources; Risk; Role; Scientist; Serum; Severities; Signal Transduction; Techniques; Testing; Therapeutic Intervention; Time; Training; Translations; United States National Institutes of Health; Work; allergic response; base; biomarker development; biomarker discovery; candidate marker; career; career development; clinical application; clinical investigation; cohort; curative treatments; enteric pathogen; food protection; gut microbiome; improved; mast cell; metabolomics; microbial composition; microbiome; microbiome composition; mouse allergy; mouse model; novel; novel marker; novel therapeutic intervention; oral tolerance; resistin; response; skills; symposium; targeted treatment

PROJECT SUMMARY/ABSTRACT: Research: Food allergy is a potentially life-threatening health condition that affects an increasing proportion of individuals in the US alone. Current daily management of patients with food allergies is limited by the unavailability of reliable biomarkers to accurately predict onset, severity and resolution of disease, and by the lack of curative treatments to replace strict avoidance of the culprit food. A deeper understanding of additional mechanisms - other than IgE - acting in food allergy pathogenesis will be key in filling these gaps. This proposal details a five-year plan to provide Dr. Crestani with the training and expertise to evaluate the role of RELMb as a novel biomarker and molecular player in food allergy building and expanding on strong preliminary observations both in a murine model of food allergy and in food allergic children. The comprehensive evaluation of the role of RELMb in food allergy holds the promise of identifying strongly needed biomarker(s) of disease and possible targets for therapeutic interventions which will be the focus of future longitudinal investigations and may significantly impact the daily care and quality of life of food allergic patients. Candidate: Dr. Crestani long-term goal is to become an independent, NIH-funded investigator focused on disease mechanisms and biomarkers of food allergy, with the goal of improving the currently suboptimal care of food-allergic individuals. There is an urgent and unmet need for novel biomarkers and therapeutic approaches in food allergies. To achieve this goal, her short-term objectives are to obtain further training in biostatistics, data analysis, laboratory techniques, as well as practical skills in cohort building and management. This will be accomplished with formal classes, collaborative work, attendance at conferences, and guidance from established mentors/scientific advisors with relevant expertise. This will result in a unique combination of practical skills and scientific knowledge that will successfully position her for an R01 application and an independent career as a physician-scientist in the field of food allergy. Environment: Dr. Crestani will be mentored by Dr. Chatila (Primary Mentor), a leader investigator in mechanisms of food allergy and head of a fully NIH-funded laboratory, and Dr. Phipatanakul (Co-Mentor), an expert in epidemiology, human cohorts, and clinical investigation in asthma and allergic diseases. Dr. Crestani has assembled an extraordinary team of advisors, including Drs. Lynda Schneider, Kari Nadeau and Rima Kaddurah-Daouk, who have committed their time, resources, and expertise to facilitate Dr. Crestani’s career development and successful completion of the proposed project. During this award period, Dr. Crestani will obtain a Master of Public Health in Clinical Effectiveness through the Harvard School of Public Health (HSPH), and complete additional complementary coursework. The academic environment created by the mentors, institution, and Harvard community at large will provide the ideal milieu for learning and research implementation that will guarantee Dr. Crestani transition into a highly successful independent investigator.

项目总结/文摘: